Tracked deals
3
3 tracked deals across 2023-2024.
Operating Company
Healthcare
P95
Leuven, Flemish Brabant, Belgium
Formerly known as P95 BV, P95 and Julius Clinical, p95 bv
Global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases, offering full-service CRO capabilities (clinical trials, epidemiology/RWE, clinical operations, pharmacovigilance, data management, biostatistics, and medical writing).
- Focus Areas
- Contract Research Organization (CRO), Epidemiology, Vaccine clinical trials
- Website
- p-95.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Addon
3 addon
P95 Acquisition Volume by Year
Last 2 years
Supporting Data
Recent Transactions
-
September 5, 2024
- Buyer
- P95 BV, Ampersand Capital Partners
- Target
- Assign DMB
- Industry
- Healthcare Services
- Location
- Tyrol, Austria
- Type
- Addon
P95 BV, a Belgium-based epidemiology and clinical solutions provider backed by Ampersand Capital Partners, has acquired Assign DMB, an Innsbruck, Austria-based clinical research organisation specializing in clinical data management and biostatistics. The deal expands P95's capabilities and capacity to run clinical and non-interventional studies—particularly in vaccines and infectious diseases—and broadens its presence in Europe and globally.
-
July 1, 2024
- Buyer
- P95 BV, Ampersand Capital Partners
- Target
- 4Clinics
- Industry
- Healthcare Services
- Location
- Belgium
- Type
- Addon
P95 BV, an Ampersand Capital Partners portfolio company, has acquired 4Clinics, a contract research organization providing data management, biostatistics, medical writing, regulatory affairs and clinical operations. The acquisition (effective July 1, 2024) integrates 4Clinics' team into the P95 group to strengthen CRO capabilities—particularly in biometrics and medical writing—and to enhance service coverage for Francophone clients.
-
- Buyer
- P95 BV, Ampersand Capital Partners
- Target
- OnQ Research
- Industry
- Healthcare Services
- Location
- Gauteng, South Africa
- Type
- Addon
P95 BV, a vaccine-focused CRO and portfolio company of Ampersand Capital Partners, has signed an agreement to merge South Africa-based contract research organization OnQ Research into P95. The deal, structured as an add-on to P95, expands P95's presence across Africa and enhances its vaccine and infectious-disease clinical research and real-world evidence capabilities.
Related Acquisition Pages
Selling a company? Get in front of buyers like P95
Turn tracked acquisition activity into an outreach-ready buyer list.